Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
SHSE:688166'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.9 Max: 1.22
Current: 0.85
During the past 10 years, the highest Debt-to-Equity Ratio of Brightgene Bio-medical Technology Co was 1.22. The lowest was 0.00. And the median was 0.90.
SHSE:688166's Debt-to-Equity is ranked worse than 85.24% of 962
companies
in the Biotechnology industry
Industry Median: 0.16
vs SHSE:688166: 0.85
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Brightgene Bio-medical Technology Co Debt-to-Equity Related Terms
Brightgene Bio-medical Technology Co Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brightgene Bio-medical Technology Co Debt-to-Equity Chart
SHSE:688166 vs VRTX, REGN, MRNA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Brightgene Bio-medical Technology Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brightgene Bio-medical Technology Co Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Brightgene Bio-medical Technology Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Brightgene Bio-medical Technology Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brightgene Bio-medical Technology Co (SHSE:688166) has a Debt-to-Equity of 0.85 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Brightgene Bio-medical Technology Co and its competitors. This is near median its historical median of 0.90. According to the industry distribution chart, Brightgene Bio-medical Technology Co ranks #820 out of 962 companies in the Biotechnology industry, placing it in the top 85.2%.
Is Brightgene Bio-medical Technology Co's Debt-to-Equity too high?
Brightgene Bio-medical Technology Co's current Debt-to-Equity of 0.85 is near median its 10-year median of 0.90. The Biotechnology industry median Debt-to-Equity is 0.16. Brightgene Bio-medical Technology Co's value of 0.85 is 431.3% above this industry median. Based on the distribution chart, Brightgene Bio-medical Technology Co ranks #820 out of 962 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Brightgene Bio-medical Technology Co has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Brightgene Bio-medical Technology Co's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Brightgene Bio-medical Technology Co ranks #820 out of 962 companies for Debt-to-Equity. This places Brightgene Bio-medical Technology Co in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Brightgene Bio-medical Technology Co's value of 0.85 is 431.3% above this benchmark. While the company's 10-year median is 0.90 vs. the industry median of 0.16, Brightgene Bio-medical Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Brightgene Bio-medical Technology Co's current Debt-to-Equity of 0.85 is 431.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Brightgene Bio-medical Technology Co and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Brightgene Bio-medical Technology Co's current Debt-to-Equity is 0.85, which is near median its own 10-year median of 0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brightgene Bio-medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Brightgene Bio-medical Technology Co (SHSE:688166) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥42.35, compared to a current price of ¥36.12 — trading 14.7% below its estimated fair value. The current Debt-to-Equity is 0.85, which is near median its 10-year median of 0.90 and 431.3% above the Biotechnology industry median of 0.16. Brightgene Bio-medical Technology Co's overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Brightgene Bio-medical Technology Co (SHSE:688166), the current Debt-to-Equity is 0.85 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Brightgene Bio-medical Technology Co (SHSE:688166) Overvalued in 2026?
Based on GuruFocus' analysis, Brightgene Bio-medical Technology Co stock appears to be undervalued.
The current stock price of ¥36.12 is trading 14.7% below its estimated GF Value™ of ¥42.35.
GuruFocus considers Brightgene Bio-medical Technology Co to be Modestly Undervalued.
Key valuation signals for SHSE:688166:
Debt-to-Equity: 0.85 (near median its 10-year median of 0.90)
GF Value™: ¥42.35 vs. price of ¥36.12 (14.7% below fair value)
Industry Position: 431.3% above the Biotechnology median (#820 of 962)
No single metric tells the full story. See the SHSE:688166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Brightgene Bio-medical Technology Co Ltd is engaged in the Research and development and production of pharmaceutical intermediates, active pharmaceutical ingredients and formulations with high technological barriers.
85GF Score
Get the complete analysis for SHSE:688166
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688166 has been successfully added to your 
